The San Francisco Bay Area Adult Glioma Survival Study

旧金山湾区成人神经胶质瘤生存研究

• 批准号: 8099448
• 负责人: MARGARET R. WRENSCH
• 金额: $ 32万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8099448
• 关键词: Adult; Adult Glioma; Alabama; Area; Asthma; Biological Assay; Biological Markers; Biopsy; Blood; Brain; Brain Neoplasms; CD14 gene; Caring; Case Series; Cells; Characteristics; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical trial protocol document; Code; Collaborations; Country; Data; Data Set; Diagnosis; Disease; Enrollment; Epidemiology; Epidermal Growth Factor Receptor; Etiology; Evaluation; Excision; Family; Foundations; Funding; Genetic; Genetic Polymorphism; Genetic Transcription; Genotype; Glioblastoma; Glioma; Goals; Grant; Hypersensitivity; IL13RA1 gene; IL4 gene; IL4R gene; IgE; Immune; Immunohistochemistry; Inflammation Mediators; Interleukin-13; Joints; Low affinity IgE receptor; Measures; Methylation; Mutation; Newly Diagnosed; O(6)-Methylguanine-DNA Methyltransferase; PTEN gene; Paper; Parents; Patients; Pharmaceutical Preparations; Pilot Projects; Polymorphic Microsatellite Marker; Prognostic Marker; Proteins; Publishing; Quality of life; Questionnaires; Radiation; Recruitment Activity; Reproduction spores; Research; Research Personnel; Resources; San Francisco; Series; Serological; Serum; Serum Markers; Single Nucleotide Polymorphism; Specimen; Stratification; Subgroup; TP53 gene; Treatment Factor; Tumor Markers; Universities; Validation; Vital Status; Work; Writing; base; case control; chemotherapy; genome-wide; improved; innovation; medical specialties; neuro-oncology; oncology service; outcome forecast; population based; prognostic; programs; receptor; response; temozolomide; tumor; validation studies

This continuation of the San Francisco Bay Area Adult Glioma Survival Study builds on 16 years of R01 funded population-based research and more than 20 years of P01 and 5 years of SPORE funded clinic- based research in the UCSF Neuro-oncology Clinic (NOC); together we have among the country's largest datasets of well-characterized adult glioma patients with polymorphism, serologic, tumor marker, demographic and other epidemiologic, treatment, and survival data. The identification of relevant tumor, serologic, constitutive polymorphic markers and patient characteristics related to glioma survival is likely to aid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneous subgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing better prognostic information to patients. Several markers identified in our ongoing and other studies warrant further research. The study's specific aims are to: (1) Continue to (a) determine vital status and relevant treatment information for population based adult onset glioma cases diagnosed 1997-99 and 2001-04 and patients accrued through the UCSF NOC 2002-2006 (total number -1500) and (b) accrue -720patients (questionnaire, blood, buccal, and tumor specimens) in the UCSF NOC 2007-2011. (Another population based series to begin May 2006 will bring the total number of patients diagnosed from 2006-2011 to -960). (2) Obtain a greater understanding of the mechanisms of improved survival among glioblastoma cases with elevated versus normal or borderline IgE levels observed in our current series and validate and expand findings to other potentially related serum markers (sCD23 and sCD14), tumor markers (CD23 protein and IL13RA2 m-RNA expression), and constitutive SNPs in IL4, IL13, IL4R, IL13RA1, and IL13RA2. These markers will also be assessed in relation to tumor TP53 mutation and expression and EGFR amplification and expression (markers measured in the parent study). (3) Determine whether polymorphisms in MGMT or tumor TP53 mutation or expression influence survival in the presence of absence of tumor MGMT methylation in patients treated with temozolomide. (4) Validate promising markers obtained from aims 2 and 3 in newly diagnosed patients seen at the UCSF NOC from July 1, 2007-June 30, 2011 in -100of these GM cases on clinical trial protocols. Our study group collaborates extensively with other brain SPORE programs and the Brain Tumor Epidemiology Consortium through sharing of specimens and data and joint grant and paper writing.

这是旧金山湾区成人脑胶质瘤生存研究的延续，建立在R01的16年基础上 资助基于人群的研究和20多年的P01和5年的孢子资助诊所- 以加州大学旧金山分校神经肿瘤学诊所(NOC)为基础的研究；我们总共拥有全国最大的 具有良好特征的成年胶质瘤患者的数据集，具有多态性、血清学、肿瘤标志物、 人口学和其他流行病学、治疗和生存数据。相关肿瘤的鉴定， 与胶质瘤生存相关的血清学、组成性多态标志物和患者特征可能 帮助为每个胶质瘤患者选择最佳治疗方案，增强同质性的定义 基于统一预后的临床试验分组，用于快速评估治疗，并在提供更好的 向患者提供预后信息。我们正在进行的研究和其他研究中发现的几个标记证明 进一步的研究。这项研究的具体目标是：(1)继续(A)确定生命状况和相关情况 1997-99年和2001-04年确诊的成人脑胶质瘤病例的治疗信息 通过加州大学旧金山分校2002-2006年NOC累积的患者(总数-1500人)和(B)累积的720名患者 (问卷、血液、口腔和肿瘤标本)在UCSF NOC 2007-2011年。(另一个人口 根据2006年5月开始的系列报告，2006-2011年确诊的患者总数将达到-960人)。 (2)进一步了解胶质母细胞瘤患者提高存活率的机制 在我们当前系列中观察到的IgE水平高于正常或接近正常水平，并验证和扩展 其他可能相关的血清标志物(sCD23和sCD14)、肿瘤标志物(CD23蛋白和 IL13RA2 m-RNA表达)，以及IL4、IL13、IL4R、IL13RA1和IL13RA2中的结构性SNP。这些 还将评估与肿瘤TP53突变和表达以及EGFR扩增有关的标记物 和表达(在父母研究中测量的标记物)。(3)确定MGMT或MGMT是否存在多态 在缺乏肿瘤MGMT的情况下，肿瘤TP53突变或表达影响患者的生存 替莫唑胺治疗患者的甲基化状态。(4)验证从AIMS 2和AIMS获得的有前景的标记 3在2007年7月1日至2011年6月30日期间在加州大学旧金山分校NOC就诊的新诊断患者中-100of 关于临床试验方案的案例。我们的研究小组与其他脑孢子程序广泛合作 和脑瘤流行病学联盟通过共享标本和数据并联合赠款和 论文写作。